Comparative Pharmacology
Head-to-head clinical analysis: ENDURONYL FORTE versus ZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENDURONYL FORTE versus ZIDE.
ENDURONYL FORTE vs ZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Enduronyl Forte is a combination of methyclothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule, and deserpidine, a Rauwolfia alkaloid that depletes catecholamines from adrenergic nerve endings, resulting in reduced peripheral vascular resistance and CNS sedation.
Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule of the nephron, reducing reabsorption of sodium and chloride and increasing excretion of water, sodium, chloride, potassium, and bicarbonate.
Oral: Initial 2.5-5 mg once daily; increase as needed to maximum 20 mg once daily.
10 mg orally once daily.
None Documented
None Documented
Clinical Note
moderateBendroflumethiazide + Digoxin
"The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Digoxin."
Clinical Note
moderateMethyclothiazide + Digoxin
"The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Digoxin."
Clinical Note
moderateHydrochlorothiazide + Digoxin
"The risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Digoxin."
Clinical Note
moderateTerminal elimination half-life: 24-48 hours (avg. 36 h); due to long half-life, requires caution in renal impairment.
6-8 hours in normal renal function; prolonged to 20-40 hours in severe renal impairment (eGFR <30 mL/min).
Renal: ~50% unchanged; Biliary/Fecal: ~50% as metabolites and unchanged drug.
Renal: 70% unchanged; Biliary/fecal: 30% (as metabolites and parent compound).
Category C
Category C
Thiazide Diuretic + Rauwolfia Alkaloid
Thiazide Diuretic
Hydroflumethiazide + Digoxin
"The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Digoxin."